Threshold Pharmaceuticals News

A A A' Product Pipeline Review A A A' H2 2011 - a new company profile report on companiesandmarkets.com Threshold Pharmaceuticals, Inc.

I've noted on a few occasions that investing in shares of biotech companies is quite challenging for the average investor.

Threshold Pharmaceuticals' news of its mega-deal with Merck KGaA was announced on Friday.

Threshold Pharmaceuticals announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

Phase 3 trial in soft tissue sarcoma on-going and randomized Phase II trial in patients with pancreatic cancer expected to report in February 2012 Threshold Pharmaceuticals, Inc today announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted ... (more)

The Federal Drug Administration controls the destiny for most biotechnology companies.